Your feedback is important to us!
We invite all our readers to share with us their views and comments about this article.
Disclaimer: Comments submitted by third parties on this site are the sole responsibility of the individual(s) whose content is submitted. The Daily Star accepts no responsibility for the content of comment(s), including, without limitation, any error, omission or inaccuracy therein. Please note that your email address will NOT appear on the site.
Alert: If you are facing problems with posting comments, please note that you must verify your email with Disqus prior to posting a comment. follow this link to make sure your account meets the requirements. (http://bit.ly/vDisqus)
The drug industry set several quarterly records for lobbying spending in the first three months of 2018 as it faced pressure from President Donald Trump's administration and lawmakers on drug pricing, generic medicines and trade.Bayer Corp., AbbVie Inc., Sanofi U.S., Novo Nordisk A/S and Celgene Corp. all reached new highs in their spending. Bayer spent $3.45 million, AbbVie $2.89 million, Sanofi $2.03 million, Celgene $1.22 million and Novo Nordisk $1.46 million. In addition to the records, Pfizer Inc. spent $4.65 million, up from $3.79 a year earlier. Abbott Laboratories spent $790,000 in the first quarter, the same as it had in the same period in 2017 .Insurers'
FOLLOW THIS ARTICLE